WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524643
CAS#: 149267-24-3
Description: Cgp 53820 is a pseudosymmetric inhibitor of HIV-1 Protease.
Hodoodo Cat#: H524643
Name: Cgp 53820
CAS#: 149267-24-3
Chemical Formula: C31H51N5O5
Exact Mass: 573.39
Molecular Weight: 573.770
Elemental Analysis: C, 64.89; H, 8.96; N, 12.21; O, 13.94
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Cgp 53820; Cgp-53820; Cgp53820.
IUPAC/Chemical Name: (S)-2-acetamido-N-((2S,3S)-4-(2-((S)-2-acetamido-3-methylbutanoyl)-1-(cyclohexylmethyl)hydrazinyl)-3-hydroxy-1-phenylbutan-2-yl)-3-methylbutanamide
InChi Key: JNBVLGDICHLLTN-DZUOILHNSA-N
InChi Code: InChI=1S/C31H51N5O5/c1-20(2)28(32-22(5)37)30(40)34-26(17-24-13-9-7-10-14-24)27(39)19-36(18-25-15-11-8-12-16-25)35-31(41)29(21(3)4)33-23(6)38/h7,9-10,13-14,20-21,25-29,39H,8,11-12,15-19H2,1-6H3,(H,32,37)(H,33,38)(H,34,40)(H,35,41)/t26-,27-,28-,29-/m0/s1
SMILES Code: C1CCCC(C1)C[N@@](NC(=O)[C@H](C(C)C)NC(C)=O)C[C@H](O)[C@H](Cc1ccccc1)NC([C@@H](NC(C)=O)C(C)C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 573.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Priestle JP, Fässler A, Rösel J, Tintelnot-Blomley M, Strop P, Grütter MG. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure. 1995 Apr 15;3(4):381-9. Erratum in: Structure 1995 Jun 15;3(6):629. PubMed PMID: 7613867.